Full Press Release Details
INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG
Mass. (June 11, 2025) - Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization
of photodynamic therapy (PDT), confirms a disclosure by the Management Board of Biofrontera AG on June 10, 2025, according
to which the two companies are in negotiations regarding a possible combination of the two companies or an adjustment of the
license and supply agreement between them. The latter could result in the transfer of certain rights and obligations from Biofrontera
AG to Biofrontera Inc. and a reduction in the transfer price for Biofrontera Inc.'s licensed products sold in the US.
terms of any such agreement or agreements have not yet been established and are subject to numerous conditions, including the
negotiation and execution of definitive agreements between the companies.
Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company
commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous
skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat
non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow
Biofrontera on LinkedIn and Twitter.
statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private
Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera's
commercial opportunities and the commercial success of its licensed products. We have based these forward-looking statements on our current
expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions
and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are
beyond our control, include, but are not limited to: the impact of any extraordinary external events; any changes in the Company's
relationship with its licensors; the ability of the Company's licensors to fulfill their obligations to the Company in a timely
manner; the Company's ability to achieve and sustain profitability; whether the current global disruptions in supply chains will
impact the Company's ability to obtain and distribute its licensed products; changes in the practices of healthcare providers,
including any changes to the coverage, reimbursement and pricing for procedures using the Company's licensed products; the uncertainties
inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier
clinical trials or trials of Ameluz in combination with BF-RhodoLED and/or RhodoLED XL in different disease indications
or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review
of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz in combination with BF- RhodoLED
and/or RhodoLED XL is consistent with the Company's expectations; the Company's ability to retain and hire key personnel;
the sufficiency of cash resources and need for additional financing; and other factors that may be disclosed in the Company's filings
with the Securities and Exchange Commission (the "SEC"), which can be obtained on the SEC's website at www.sec.gov.
Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are
made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any
such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as